PDE3B and HBB are key prognostic biomarkers driving cell proliferation and regulating immune microenvironment in breast cancer.

IF 2.5 3区 生物学
Bolong Yin, Xiangrong Luo, Xuebo Yan, Hui Shen, Jianping Jiang
{"title":"PDE3B and HBB are key prognostic biomarkers driving cell proliferation and regulating immune microenvironment in breast cancer.","authors":"Bolong Yin, Xiangrong Luo, Xuebo Yan, Hui Shen, Jianping Jiang","doi":"10.1186/s41065-025-00470-z","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Breast cancer is a heterogeneous malignancy with diverse tumor subpopulations and complex tumor-immune interactions. This study explores the prognostic and functional roles of PDE3B and HBB in breast cancer, focusing on their contributions to proliferation and immune microenvironment modulation.</p><p><strong>Methods: </strong>Single-cell RNA sequencing (scRNA-seq) and TCGA data were analyzed to identify malignant subpopulations and prognostic genes. Differential gene expression, KEGG enrichment, LASSO regression, and Kaplan-Meier survival analyses were performed. Immune infiltration was assessed using EPIC deconvolution. Functional validation included qRT-PCR, IHC, Western blot, and proliferation assays in MDA-MB-231 cells.</p><p><strong>Results: </strong>Malignant cell type 3 exhibited the highest proliferative potential. PDE3B and HBB were identified as prognostic markers, strongly associated with poor survival and immune cell infiltration. Overexpression of these genes enhanced proliferation, while their knockout suppressed it.</p><p><strong>Conclusion: </strong>PDE3B and HBB drive breast cancer proliferation and immune modulation, making them promising biomarkers and therapeutic targets. Further research should assess their potential in targeted therapies.</p>","PeriodicalId":12862,"journal":{"name":"Hereditas","volume":"162 1","pages":"97"},"PeriodicalIF":2.5000,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12131617/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hereditas","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1186/s41065-025-00470-z","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Breast cancer is a heterogeneous malignancy with diverse tumor subpopulations and complex tumor-immune interactions. This study explores the prognostic and functional roles of PDE3B and HBB in breast cancer, focusing on their contributions to proliferation and immune microenvironment modulation.

Methods: Single-cell RNA sequencing (scRNA-seq) and TCGA data were analyzed to identify malignant subpopulations and prognostic genes. Differential gene expression, KEGG enrichment, LASSO regression, and Kaplan-Meier survival analyses were performed. Immune infiltration was assessed using EPIC deconvolution. Functional validation included qRT-PCR, IHC, Western blot, and proliferation assays in MDA-MB-231 cells.

Results: Malignant cell type 3 exhibited the highest proliferative potential. PDE3B and HBB were identified as prognostic markers, strongly associated with poor survival and immune cell infiltration. Overexpression of these genes enhanced proliferation, while their knockout suppressed it.

Conclusion: PDE3B and HBB drive breast cancer proliferation and immune modulation, making them promising biomarkers and therapeutic targets. Further research should assess their potential in targeted therapies.

PDE3B和HBB是乳腺癌中驱动细胞增殖和调节免疫微环境的关键预后生物标志物。
背景:乳腺癌是一种异质性恶性肿瘤,具有不同的肿瘤亚群和复杂的肿瘤免疫相互作用。本研究探讨PDE3B和HBB在乳腺癌中的预后和功能作用,重点关注它们在增殖和免疫微环境调节中的作用。方法:分析单细胞RNA测序(scRNA-seq)和TCGA数据,鉴定恶性亚群和预后基因。差异基因表达、KEGG富集、LASSO回归和Kaplan-Meier生存分析。采用EPIC反褶积法评估免疫浸润。功能验证包括在MDA-MB-231细胞中进行qRT-PCR、免疫组化、Western blot和增殖试验。结果:3型恶性细胞增殖能力最强。PDE3B和HBB被确定为预后标志物,与生存不良和免疫细胞浸润密切相关。这些基因的过度表达促进了增殖,而敲除它们则抑制了增殖。结论:PDE3B和HBB驱动乳腺癌增殖和免疫调节,是有前景的生物标志物和治疗靶点。进一步的研究应该评估它们在靶向治疗中的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Hereditas
Hereditas Biochemistry, Genetics and Molecular Biology-Genetics
CiteScore
3.80
自引率
3.70%
发文量
0
期刊介绍: For almost a century, Hereditas has published original cutting-edge research and reviews. As the Official journal of the Mendelian Society of Lund, the journal welcomes research from across all areas of genetics and genomics. Topics of interest include human and medical genetics, animal and plant genetics, microbial genetics, agriculture and bioinformatics.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信